SPIA
CCCC icon

Steward Partners Investment Advisory’s C4 Therapeutics CCCC Stock Holding History

Steward Partners Investment Advisory’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$590 – 3325
2022
Q4 		$590 Buy
+100
New +$829 ﹤0.01% 3182

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steward Partners Investment Advisory's CCCC Position: Q1 2023 in Review

Steward Partners Investment Advisory sold out of C4 Therapeutics (CCCC) in Q1 2023, closing a stake of 100 shares — an estimated $590 sold.

Steward Partners Investment Advisory first reported a position in CCCC in Q4 2022 and held it in 1 quarter. The position peaked at $590 in Q4 2022. 120 funds tracked by Wall St. Rank hold CCCC as of Q1 2023.

  • Steward Partners Investment Advisory reported no remaining C4 Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 100 C4 Therapeutics shares in Q1 2023, an estimated $590.
  • Steward Partners Investment Advisory first reported a position in C4 Therapeutics in Q4 2022 and held it in 1 quarter.
  • Steward Partners Investment Advisory's C4 Therapeutics position peaked at $590 in Q4 2022.
  • 120 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.